The data do not allow to identify particular risk factors (gender, age) that make blood clots more likely to occur after administration of the second dose of Vaxzevria (AstraZeneca vaccine).

This was announced by the European Medicines Agency, at the conclusion of a further analysis of the data, which confirm the provisional opinion expressed by the agency last April .

"Although spontaneous reports, when related to exposure, have suggested that the risk may be greater in women and younger adults and lower after the second dose than the first dose - reads a note from the EMA -, the limitations of the way data are collected mean that none of these differences could be confirmed. "

The Agency's recommendation remains to administer a second dose of Vaxzevria between four and twelve weeks after the first. There is no evidence that delaying the second dose has any influence on the risk of clots.

Finally, the EMA reports that it is not possible to make definitive recommendations on the use of a different vaccine for the second dose.

(Uniononlihne / F)